Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

Follow @BCD_AACR on Twitter!

From the Current Issue

  • Research Articles | Free Article
    A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms
    Yihong Guan, Anand D. Tiwari, James G. Phillips, Metis Hasipek, Dale R. Grabowski, Simona Pagliuca, Priyanka Gopal, Cassandra M. Kerr, Vera Adema, Tomas Radivoyevitch, Yvonne Parker, Daniel J. Lindner, Manja Meggendorfer, Mohamed Abazeed, Mikkeal A. Sekeres, Omar Y. Mian, Torsten Haferlach, Jaroslaw P. Maciejewski and Babal K. Jha
    Blood Cancer Discov March 1 2021 2 (2) 146-161; DOI:10.1158/2643-3230.BCD-20-0173

    2HG accumulation from IDH1/2 mutation induces synthetic lethality in TET2-mutant cells by reducing TET activity below essentially required. A new TET inhibitor mimics 2HG and selectively restricts clonal evolution of TET2-mutant cells in vitro and in vivo.

  • Research Brief | Free Article
    Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
    Ahmad S. Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Marina Konopleva, Sherry A. Pierce, Sa A. Wang, Guilin Tang, Veronica Guerra, Bachar Samra, Naveen Pemmaraju, Elias Jabbour, Nicholas J. Short, Ghayas C. Issa, Maro Ohanian, Guillermo Garcia-Manero, Kapil N. Bhalla, Keyur P. Patel, Koichi Takahashi, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi and Naval Daver
    Blood Cancer Discov March 1 2021 2 (2) 125-134; DOI:10.1158/2643-3230.BCD-20-0143

    Genetic patterns underlying resistance to Flt3-targeted therapies in AML reveal distinct drivers associated with relapse on type 1 versus type 2 inhibitors and link mutation emergence with clinical outcomes.

  • Research Articles | Free Article
    TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia
    Seongseok Yun, Nicole D. Vincelette, Xiaoqing Yu, Gregory W. Watson, Mario R. Fernandez, Chunying Yang, Taro Hitosugi, Chia-Ho Cheng, Audrey R. Freischel, Ling Zhang, Weimin Li, Hsinan Hou, Franz X. Schaub, Alexis R. Vedder, Ling Cen, Kathy L. McGraw, Jungwon Moon, Daniel J. Murphy, Andrea Ballabio, Scott H. Kaufmann, Anders E. Berglund and John L. Cleveland
    Blood Cancer Discov March 1 2021 2 (2) 162-185; DOI:10.1158/2643-3230.BCD-20-0029

    MYC directly inhibits expression of TFEB, which serves as a tumor suppressor in AML via promoting myeloid differentiation and cell death. TFEB induces IDH1/2 expression to establish myeloid epigenetic programs, and it is a druggable target in AML.

  • Research Brief | Free Article
    Ectopic Humanized Mesenchymal Niche in Mice Enables Robust Engraftment of Myelodysplastic Stem Cells
    Syed A. Mian, Ander Abarrategi, Kar Lok Kong, Kevin Rouault-Pierre, Henry Wood, Caroline A. Oedekoven, Alexander E. Smith, Antoniana Batsivari, Linda Ariza-McNaughton, Peter Johnson, Thomas Snoeks, Ghulam J. Mufti and Dominique Bonnet
    Blood Cancer Discov March 1 2021 2 (2) 135-145; DOI:10.1158/2643-3230.BCD-20-0161

    Human bone marrow stromal niche engineering in mice supports long-term engraftment of primary patient MDS cells with preserved disease characteristics.


OnlineFirst Articles

Load more

Trending - Altmetric

No Altmetric data available.
Advertisement
Back to top